flow trial semaglutide results Effects of with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial Ozempic® (semaglutide injection)

PlexusDx practitioners monitor patients regularly through telehealth follow-ups, track side effect patterns, and adjust treatment plans to maximize safety and efficacy for younger users

For example, semaglutide 2.4 mg (Wegovy) has been shown to reduce major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, even in the absence of diabetes

Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study

However, absorption limitations and lower bioavailability make traditional injections the evidence-backed choice for maximum weight loss results, with clinical trials showing injected GLP-1 receptor agonists produce 15-22% body weight reduction over 68 weeks

Find the best weight loss dietitian near you, covered by insurance